Ladenburg, Germany, 21 July 2020 - Heidelberg Pharma AG today announced that it has secured a financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany, (dievini). dievini will provide the Company with up to EUR 15 million. The detailed form of the financing will be decided by the management and supervisory boards of Heidelberg Pharma AG as well as dievini at a later date.The financing commitment will enable Heidelberg Pharma to advance development candidates from its proprietary project portfolio and start the necessary work. This will maintain the financing reach until mid-2021.
Search
Recent Posts
See AllGeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy testing services. GeneWerk GmbH, a cell and gene therapy testing laboratory focused on providing preclinica